A Review Article on Novel Antifungal Agents with Different Heterocyclic Nucleus

Hemophilia B is a congenital X-linked recessive bleeding disorder caused by mutations in the F9 gene, leading to a deficiency in clotting factor IX. Mutational analysis identifies genetic mutations affecting factor IX production, aiding diagnosis, genetic counseling, and personalized treatment. Techniques like Sanger sequencing and next-generation sequencing (NGS) are used to detect these mutations. Sanger offers detailed single-gene analysis, while NGS provides broader, high-throughput screening. Identifying mutations helps predict disease severity, guide carrier detection, and enable prenatal diagnosis, supporting family planning. Challenges in mutational analysis include detecting complex mutations, high costs, and interpreting rare variants' clinical significance. Hemophilia B shows clinical variability due to multiple mutations and genetic modifiers, complicating severity predictions and treatment outcomes. Understanding genotype-phenotype correlations aids in tailoring factor IX replacement therapy and other interventions. Gene therapy and emerging treatments, like bypassing agents, offer promise for long-term management by targeting specific F9 mutations. Genetic counseling is crucial for families, particularly carrier females, providing options like prenatal diagnosis. Mutational analysis has advanced personalized care strategies, though managing inhibitor formation from therapy mismatches remains challenging. Future advancements in detection techniques may enhance treatment precision, prevent inhibitor formation, and improve outcomes for Hemophilia B patients.